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Abstract
Background: Antibodies targeting Plasmodium falciparum sporozoites play a key role in human immunity to
malaria. However, antibody mechanisms that neutralize sporozoites are poorly understood. This has been a major
constraint in developing highly efficacious vaccines, as we lack strong correlates of protective immunity.
Methods: We quantified the ability of human antibodies from malaria-exposed populations to interact with human
complement, examined the functional effects of complement activity against P. falciparum sporozoites in vitro, and
identified targets of functional antibodies. In children and adults from malaria-endemic regions, we determined the
acquisition of complement-fixing antibodies to sporozoites and their relationship with antibody isotypes and
subclasses. We also investigated associations with protective immunity in a longitudinal cohort of children (n = 206)
residing in a malaria-endemic region.
Results: We found that antibodies to the major sporozoite surface antigen, circumsporozoite protein (CSP), were
predominately IgG1, IgG3, and IgM, and could interact with complement through recruitment of C1q and
activation of the classical pathway. The central repeat region of CSP, included in leading vaccines, was a key target
of complement-fixing antibodies. We show that antibodies activate human complement on P. falciparum
sporozoites, which consequently inhibited hepatocyte cell traversal that is essential for establishing liver-stage
infection, and led to sporozoite death in vitro. The natural acquisition of complement-fixing antibodies in malaria-
exposed populations was age-dependent, and was acquired more slowly to sporozoite antigens than to merozoite
antigens. In a longitudinal cohort of children, high levels of complement-fixing antibodies were significantly
associated with protection against clinical malaria.
Conclusions: These novel findings point to complement activation by antibodies as an important mechanism of
anti-sporozoite human immunity, thereby enabling new strategies for developing highly efficacious malaria
vaccines. We also present evidence that complement-fixing antibodies may be a valuable correlate of protective
immunity in humans.
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Background
Malaria is a substantial cause of global morbidity and
mortality, and the effectiveness of current interventions is
under threat due to increasing reports of drug and insecti-
cide resistance. To achieve malaria control and elimin-
ation, there is a pressing need to develop and license
highly efficacious malaria vaccines. This is a global prior-
ity, and the World Health Organization has set the ambi-
tious goal to license a malaria vaccine that is at least 75%
efficacious against clinical malaria by 2030 [1]. Currently,
there is no licensed vaccine against Plasmodium falcip-
arum, the main cause of malaria morbidity and mortality
[2]. Vaccine development is significantly challenged by the
lack of knowledge on the targets and mechanisms of func-
tional immunity that confer protection against malaria,
and a lack of correlates of protection. Defining these
mechanisms is crucial for identifying strong correlates of
protection, which will aid vaccine evaluation and enhance
current vaccine candidates by inducing potent functional
immune responses [3].
Plasmodium sporozoites are transmitted to humans
when an infected female Anopheles mosquito probes the
skin in search of a blood vessel [4]. Sporozoites are pas-
sively carried in the blood circulation to the liver, where
they develop within hepatic cells, generating thousands
of merozoites [5], which initiate blood-stage replication
and subsequently cause symptomatic and severe malaria.
Vaccines targeting sporozoites are attractive because
fewer than 100 sporozoites are transmitted to humans
[6] and blocking sporozoites will prevent infection and
subsequent disease. Even partial immunity to sporozoites
could reduce the number of successful hepatocyte infec-
tions and subsequent blood-stage parasitemia, which
may confer protection against clinical malaria or reduce
disease severity.
The predominant sporozoite surface antigen is circum-
sporozoite protein (CSP). Antibodies to CSP have been dir-
ectly shown to confer protection against infection in animal
malaria models [7, 8], have had some association with pro-
tection in human vaccine trials [9], and can be acquired
through natural exposure to malaria [10, 11]. However, an
enduring question that remains unanswered is how anti-
bodies to sporozoites and CSP function to protect against
infection. The most advanced malaria vaccine candidate,
RTS,S/AS01 (RTS,S), is based on the central-repeat and C-
terminal regions of CSP [12], and induces antibody and
CD4+ T cell responses [13]. RTS,S was only partially effica-
cious against clinical malaria in phase III clinical trials (vac-
cine efficacy 29–36% in children aged 5–17 months after
48 months of follow-up) [14], and the functional mecha-
nisms of vaccine-induced immunity remain unknown.
These knowledge gaps severely impair our ability to
enhance current vaccines and to design new vaccines that
induce potent functional immunity for greater efficacy.
Sporozoites can take several hours to reach the liver
[4], leaving them highly susceptible to immune attack at
the inoculation site in the skin and in the circulation.
The success of invasion and development in the liver is
dependent on sporozoite motility, which includes: (i)
gliding to migrate out of the skin [15], (ii) traversal to
pass through cells, and (iii) hepatocyte invasion and
maturation [16]. Anti-CSP antibodies can neutralize mo-
tility in vitro, although the relationship between function
and protective immunity has not been demonstrated
[17–19], and direct inhibitory activity of antibodies gen-
erally requires relatively high antibody concentrations
[18, 20]. Furthermore, there are few data on whether the
immunoglobulin G (IgG) subclass influences antibody
function and what epitopes are primarily targeted.
We hypothesized that antibodies of the right type and
specificity may fix and activate complement to neutralize
P. falciparum sporozoites. Harnessing complement ac-
tivity using antibodies is an attractive mechanism of
functional immunity because complement could act
early following inoculation to combat sporozoites (Add-
itional file 1: Figure S1). Complement activation can
occur via the classical pathway whereby C1q interacts
with immune complexes, referred to as C1q-fixation
[21]. This leads to sequential activation of downstream
complement proteins such as C3, and formation of the
membrane attack complex (MAC), which mediates cell
death. Activation can also occur via the alternative path-
way involving direct C3 activation against pathogens
[21]. Currently it is unknown if P. falciparum sporozo-
ites are susceptible to complement deposition and
attack, and whether antibodies function to promote
complement activation and consequently neutralize
sporozoite function or lead to sporozoite death.
We investigated the ability of antibodies to CSP and P.
falciparum sporozoites to recruit human complement
proteins, and demonstrated the functional effects of
complement activation against sporozoites in vitro. We
also explored the natural acquisition of complement-
fixing antibodies, and then assessed whether functional
antibodies were associated with protection in a prospect-
ive longitudinal cohort of children.
Methods
Aims and study participants
There were several aims to this study: (i) to determine
whether human antibodies fix complement, (ii) to ex-
plore the relationship between functional antibodies and
isotype, subclass, and specificity, (iii) to examine the nat-
ural acquisition of functional antibodies in young chil-
dren, and (iv) to assess the association between
functional antibodies and protection against malaria in
children. To meet these aims, we tested antibody sam-
ples from previously described cohort studies as
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summarized below. Note that all three study sites were
considered to be malaria holo- or hyper-endemic, and
no bed nets of any type were in place at this time.
(i) To maximize the likelihood of detecting functional
anti-CSP antibodies, we tested two cohorts of malaria-
exposed adults from distinct areas, as anti-CSP anti-
bodies have been previously reported to be acquired
with age as a result of repeated malaria exposure. Sera
from adults living in Madang District (Papua New
Guinea, PNG, N = 116) were collected in 2001 and 2002
[22], and plasma from adults living in the Kanyawegi
subdistrict, Kisumu county (Kenya, N = 104) were
collected in August 2007 [23].
(ii) We then preferentially selected 30 samples from
each adult cohort (PNG and Kenyan) to characterize the
antibody response further, based on IgG/C1q-fixation
reactivity to CSP and sample availability.
(iii) The majority of malaria morbidity occurs in chil-
dren under 5 years, and so we tested a cohort of young
children (0.3–5.9 years) to examine the acquisition of
functional antibodies, and compared this cohort to adults
from the same area. Plasma from children/adults living in
the Chulaimbo subdistrict, Kisumu county (Kenya, N =
75) were collected in February and March 2007 [24]. Sam-
ples were categorized into groups based on the median
ages of 0.5, 1, 2, 5 and 35 years (age ranges were 0.3–0.7,
1–1.5, 1.8–3.0, 4.7–5.9, and 19.6–69.2 with n = 11, n = 14,
n = 18, n = 16, and n = 16, respectively).
(iv) To assess the relationship between functional anti-
bodies and protection against malaria, we tested samples
from a longitudinal prospective treatment-to-reinfection
study. Plasma samples from children living in Madang
Province (PNG, N = 206) aged 5–14 years (median = 9.
3 years) were collected at enrolment in 2004 and 2005
[25]. Children were treated to clear parasitemia present
at baseline, and then actively followed every 2 weeks for
symptomatic illness and parasitemia, and by passive case
detection over a period of 6 months. A clinical episode
of P. falciparum malaria was defined as fever and P.
falciparum parasitemia >5000 parasites/μl.
We also generated two pools of Kenyan donors with
high C1q-fixation reactivity from the adult Kenyan
cohort. Pool 1 (n = 10) was used in IgG-purification
experiments, using the Melon gel purification kit as de-
scribed by the manufacturer (Thermo Fisher Scientific,
Waltham, USA). Pool 2 (n = 19) was used in the in vitro
hepatocyte traversal experiments. To minimize potential
background reactivity from any residual complement
that may remain after heat inactivation, antibodies from
pool 2 (and a control pool from residents of Melbourne,
Australia) were purified by ammonium sulfate precipita-
tion [26]. Sterile saturated ammonium sulfate was slowly
added with continuous agitation to plasma (diluted 1/5
in sterile saline) to a final concentration of 50%.
Following 30 min incubation on ice, the precipitate was
pelleted (20,000 relative centrifugal force (RCF) × 10 min),
then washed in 50% sterile saturated ammonium sulfate.
The precipitate was repeatedly washed in excess
phosphate-buffered saline (PBS) using a centrifugation
concentration device, as described by the manufacturer
(100 kDa cut-off, Millipore, Burlington, USA), and re-
suspended to the same starting volume of plasma.
Parasites
Aseptic, purified, non-attenuated cryopreserved P. falcip-
arum 3D7 sporozoites (Sanaria, Rockville, USA) were pro-
vided by PATH’s Malaria Vaccine Initiative or purchased
from Sanaria. Freshly dissected P. falciparum NF54 and
NF166.C8 sporozoites were generated at Radboud
University Medical Center (Radboudumc, Nijmegen, The
Netherlands), as described previously [20, 27].
Antigens and antibodies
Recombinant P. falciparum CSP was expressed in Pichia
pastoris and purified using high-performance liquid chro-
matography (Sanaria) [28]. The protein was based on the
3D7 sequence beginning at amino acid residue 50 and
contained 22 NANP repeats and four NVDP repeats. A
peptide representative of the P. falciparum CSP central re-
peat B-cell epitope (NANP)15 was synthesized and purified
using high-performance liquid chromatography (Life Tein,
Hillsborough, USA). Full-length recombinant merozoite
surface protein 2 (MSP2) was expressed in Escherichia coli
as previously described [29].
Rabbits were immunized with three doses of 200 μg
CSP 4 weeks apart (the first immunization was adminis-
tered in complete Freud’s adjuvant and the last two in
incomplete Freud’s adjuvant). The terminal bleed was
obtained 12 days after the final immunization, and anti-
CSP IgG was purified at the Walter and Eliza Hall Insti-
tute. Pre-immune IgG was purified in-house using the
Melon gel purification kit, as described by the manufac-
turer (Thermo Fisher Scientific). Animal immunizations
were approved by the Animal Ethics Committee of the
Walter and Eliza Hall Institute. We were provided with
subclass switched mouse anti-NANP monoclonal anti-
bodies (MAbs) 2H8-IgG1/IgG2a and 3C1-IgG1/IgG3
(LakePharma, Belmont, USA) by PATH’s MVI [30].
Antibody isotypes and subclasses by enzyme-linked
immunosorbent assay
The procedure for the enzyme-linked immunosorbent
assay (ELISA) was as follows. Flat bottom 96-
well MaxiSorp plates (Thermo Fisher Scientific) were
coated with 0.5 μg/ml antigen in PBS overnight at 4 °C.
Plates were washed thrice in PBS-Tween20 0.05% (v/v),
blocked using 1% (w/v) casein in PBS for 2 h at 37 °C,
and then washed again. Human antibody samples were
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applied in duplicate at 1/2000 (IgG/M) or 1/500 (IgG
subclasses) dilutions in 0.1% (w/v) casein in PBS
(diluting buffer) for 2 h at room temperature (RT), and
then washed. Antibody isotypes were detected using goat
anti-human IgG/IgM horse radish peroxidase (HRP)
conjugated antibodies (Millipore) at 1/2500 dilution for
1 h at RT, followed by washing and incubation with 2,2′-
azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)
substrate (Sigma-Aldrich, St. Louis, USA) for 1 h at RT in
the dark. The reaction was stopped using 1% (w/v) sodium
dodecyl sulfate in PBS. The optical density (OD) was mea-
sured at 405 nm. IgG subclasses were detected using
mouse anti-human IgG1/IgG2/IgG3/IgG4 antibodies
(Invitrogen) at 1/1000 dilution for 1 h at RT, followed by
washing and incubation with goat anti-mouse IgG HRP
conjugated antibodies (Millipore) at 1/1000 dilution for
1 h at RT. Plates were washed and incubated with a tetra-
methylbenzidine substrate (Sigma-Aldrich) for 1 h at RT
in the dark, and the reaction was stopped using 1 M
sulfuric acid (OD measured at 450 nm). Rabbit and mur-
ine antibodies were detected using goat anti-rabbit/mouse
HRP conjugated antibodies (Millipore, Abcam) at 1/2000
and ABTS substrate.
Complement-fixation by ELISA and Western blot
Again, 96-well flat bottom MaxiSorp plates were coated
with antigen, blocked and washed as described above.
Human antibody samples were applied in duplicate at 1/
100–1/250 dilution for 2 h at RT, and then washed.
Plates were incubated with 10 μg/ml human C1q, C1q-
depleted serum (Millipore), C5-depleted serum (for C2/
C3/C4 fixation, Millipore) or fresh pooled non-immune
serum (for C5b-C9 fixation) at 1/10 dilution for 30 min
at RT, washed, and detected using anti-C1q/C2/C3/C4/
C5b-C9 antibodies at 1/1000–1/2000 dilution (Dako,
Santa Clara, USA; Abcam, Cambridge, UK; Millipore)
for 1 h at RT. Plates were washed and incubated with
the appropriate HRP conjugated antibodies (Abcam,
Sigma-Aldrich, Millipore) at 1/2000 dilution for 1 h at
RT followed by washing. Complement-fixation was
detected using a tetramethylbenzidine substrate as
described above (MSP2 experiments utilized ABTS).
Complement-fixation using murine and rabbit anti-
bodies were conducted using the same methods.
Complement-fixation to 3D7 P. falciparum sporozoites
by ELISA was conducted using the same method as
above (coating of 10,000 cells per well); however, all
incubation times did not exceed 1 h, were conducted at
RT, and the washing buffer contained PBS only. To
measure complement-fixation by Western blot, 10,000
sporozoites were incubated with human antibody sam-
ples at 1/10 dilution and fresh normal human serum at
25% in PBS for 15 min at 37 °C with agitation. Sporozo-
ites were washed twice in cold protease inhibitor (1600 x
RCF, 4 min), processed for SDS-PAGE and then blotted
into nitrocellulose membrane (under reducing condi-
tions). The membrane was blocked in 10% (w/v)
skimmed milk in PBS-Tween20 0.5% (v/v) and probed
using anti-C1q/iC3b antibodies (Serotec, Kidlington,
UK) followed by HRP conjugated antibodies, with mem-
brane stripping (Sigma-Aldrich), washing and blocking
in between. Protein bands were detected using chemilu-
minescent substrate and autoradiography film (GE Life
Sciences, Chicago, USA). Membranes were also probed
with anti-CSP antibodies as a loading control.
Experimental controls and standardization
Human antibody samples (serum/plasma) tested by
ELISA were excluded if duplicates varied by greater than
25% (unless duplicates differed by OD < 0.1). OD values
were corrected by subtracting the background reactivity
of control wells containing no serum or plasma. Cohort
experiments that spread across multiple ELISA plates
were standardized for plate-to-plate variation using posi-
tive control wells containing highly reactive samples
from malaria-exposed individuals. Malaria-naïve sera
from Melbourne donors were tested as negative con-
trols. Test samples giving ODs greater than the mean +
3 standard deviations of malaria naïve controls were
considered positive. This positive cut-off value was used
to convert OD into arbitrary units (AU) as follows: AU
= sample corrected OD / positive cut-off OD, so that
samples with AU > 1 were considered positive. All
plasma/serum samples were heat inactivated at 56 °C for
45 min prior to use.
Sporozoite cell traversal
Traversal was conducted as previously described [20]
using freshly dissected P. falciparum NF54 and NF166.
C8 sporozoites. Briefly, sporozoites were pre-incubated
with pooled human antibody samples (malaria-exposed
Kenyan and malaria-naïve Melbourne pools purified by
ammonium sulfate precipitation) at 1/10 dilution, or
vaccine-induced rabbit anti-CSP IgG and pre-immune
IgG at 1 and 10 μg/ml, for 30 min on ice. Sporozoite/
antibody samples were added to HC-04 cells seeded on
96-well plates, along with 10% normal human serum
(NHS; active complement) or heat-inactivated serum
(HIS; inactive complement), and tetramethylrhodamine
(Rh) labelled dextran (50,000 sporozoites and 50,000
HC-04 cells per well). Sporozoites were allowed to
traverse HC-04 cells under these conditions (in the pres-
ence of immune/non-immune antibodies and active/in-
active complement) for 2 h at 37 °C in 5% CO2, and
were then washed in PBS. HC-04 cells were then trypsi-
nized, washed in 10% fetal bovine serum in PBS, and re-
suspended in 1% paraformaldehyde. Traversed HC-04
cells were measured as Rh positive, and quantified by
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flow cytometry using the Cyan (Beckman Coulter) and
FlowJo software (gating strategy shown in Additional
file 1: Figure S2A). The percentage of Rh positive cells
was corrected for background reactivity using HC-04
cells treated with dextran only. Traversal inhibition by
immune antibodies (Kenyan pool and rabbit anti-CSP
IgG) compared to non-immune antibodies (Melbourne
pool and rabbit pre-immune IgG) in the presence of
NHS and HIS was calculated as
ð1− %traversed cells in the presence of immune antibodies%traversed cells in the presence of non‐immune antibodiesÞ  100
Sporozoites were also pre-incubated with anti-CSP
MAb 3SP2 as a positive control.
Sporozoite cell death by flow cytometry
Altogether, 50,000 3D7 P. falciparum sporozoites were
incubated with rabbit anti-CSP antibodies at 1/10 dilu-
tion and 20% human serum (normal or C5-depleted) for
10 min at 37 °C. Sporozoites were placed on ice and
dead cells were stained using the DNA-binding dye, pro-
pidium iodide (PI). PI positive cells were quantified by
flow cytometry using FACSVerse (BD Biosciences) and
FlowJo software (gating strategy shown in Additional
file 1: Figure S2B).
Statistical analysis
Data were analyzed using GraphPad Prism version 6.
05 and Stata 13.1. The following two-tailed non-
parametric tests were performed where appropriate:
Spearman’s correlation coefficient (rho), Wilcoxon
matched-pairs signed rank test, Man Whitney U test,
and Kruskal–Wallis test. To investigate the associ-
ation between anti-CSP IgG and IgM with C1q fix-
ation in PNG adults, we performed a multiple linear
regression with robust standard errors. To evaluate
associations between specific antibodies (C1q fixation
activity or IgG reactivity to CSP) and malaria risk in
the longitudinal study, Kaplan–Meier survival curves
were plotted to show the cumulative proportion of
children who had experienced an episode of malaria
during follow-up, stratified by antibody response
group defined as negative, low positive, and high
positive (positive samples were defined as those with
reactivity > 3 standard deviations above the mean of
the malaria-naïve control samples, high-positive sam-
ples were those defined as being above the median of
the positive samples, and low positive were those
below the median of positive samples). Hazard ratios
(HRs) of the risk of malaria during follow-up were
calculated using the Cox proportional hazards model
(using the first episodes of malaria only), and adjusted
HRs were calculated by including age, location of
residence, and parasitemia status at enrolment [25].
Results
Naturally acquired anti-CSP antibodies are predominately
IgG1, IgG3, and IgM
Antibody isotype and subclass influence the ability to fix
C1q and activate the classical pathway. Therefore, we
characterized naturally acquired antibodies to the most
abundant sporozoite surface protein, CSP, for possible
interaction with complement. We measured antibody
levels by ELISA and converted OD into AU. Among a
selection of malaria-exposed adults from PNG and
Kenya (n = 30 in each group), 40% and 75% were positive
for anti-CSP IgM, respectively (Fig. 1a and b). IgM anti-
bodies are potent complement activators whereas IgG
complement activity is mediated primarily by the IgG1
and IgG3 subclasses, whereby IgG3 generally has greater
activity [31]. The predominant subclasses in PNG and
Kenyan adults were the complement-fixing subclasses
IgG1 (seropositivity 67% and 100%, respectively) and
IgG3 (seropositivity 76% and 97%, respectively). In con-
trast, the seroprevalence of IgG2 and IgG4 antibodies
were lower (PNG seropositivity 15% and 7%; Kenyan
seropositivity 48% and 16%, respectively).
Naturally acquired human antibodies and vaccine-
induced antibodies promote complement-fixation to
recombinant CSP
We next investigated whether naturally acquired anti-
bodies in humans and vaccine-induced antibodies in ani-
mals were capable of promoting complement activation.
Since the classical pathway is initiated by antibody-C1q
interactions [31, 32], we tested whether antibodies to
CSP could fix C1q using ELISA-based methods. Among
a selection of PNG adults (n = 30), 77% of individuals
were positive for this activity. Furthermore, human anti-
CSP antibodies also fixed other complement compo-
nents downstream of C1q, including C4, C2, C3, and
C5b-C9 (reflecting MAC-formation) [21], all of which
strongly positively correlated with C1q-fixation (Spear-
man’s correlation coefficient rho = 0.794, 95% confi-
dence interval (CI) 0.591 to 0.903; rho = 0.763, 95% CI 0.
548 to 0.884; rho = 0.784, 95% CI 0.584 to 0.895; and
rho = 0.836, 95% CI 0.674 to 0.921; p < 0.001 for all tests,
respectively) (Fig. 1c and d). We confirmed that C3-
fixation was mediated by anti-CSP antibodies and the
classical pathway and not by the alternative pathway
using C1q-depleted serum as a source of complement,
which significantly reduced reactivity by 61–88% (p = 0.
031) (Fig. 1e). We next addressed whether complement-
fixing antibodies could be elicited by CSP immunization
of rabbits, as rabbit IgG is known to engage [33] and ac-
tivate the human complement [34]. Vaccine-induced IgG
demonstrated strong reactivity to recombinant CSP and
to the central repeat region of CSP represented by the
synthetic (NANP)15 peptide, and promoted C1q and C3-
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fixation to CSP (Fig. 2). Collectively these data demon-
strate that antibodies can fix C1q and activate the
classical pathway against CSP.
Anti-CSP antibody isotype and subclass are associated
with complement-fixation
We examined the relationship between IgG and C1q-
fixation to CSP in two different cohorts of malaria-
exposed adults from PNG (n = 116) and Kenya (n =
104). Although there was a consistent positive trend be-
tween IgG and C1q-fixation in both populations, we ob-
served marked differences in the ability to fix C1q
among individuals with similar levels of anti-CSP IgG
(Fig. 3). This suggests that additional factors or antibody
properties influence this function.
To confirm that IgG alone is capable of promoting
C1q-fixation, we compared purified IgG and whole
plasma from a pool of Kenyan adults with high levels of
C1q-fixing antibodies (n = 10). Purified IgG could fix
C1q, but less effectively than plasma, possibly due to the
loss of IgM, which is known to activate complement po-
tently (Additional file 1: Figure S3A). To explore in more
detail the relative contributions of IgG and IgM in pro-
moting C1q-fixation, we performed a linear regression
with data from PNG adults (n = 116). For every unit in-
crease in anti-CSP IgG, there was an increase in C1q-
fixation of 0.785 AU (95% CI 0.585 to 0.985; p < 0.001),
and this value was lower after adjusting for anti-CSP
IgM (0.579, 95% CI 0.342 to 0.851; p < 0.001) (Additional
file 1: Table S1). The inclusion of IgM only slightly
improved the fit of the model (IgG R-squared = 0.67 and
IgG/IgM R-squared = 0.71), suggesting that most vari-
ation in C1q-fixation responses could be explained by
anti-CSP IgG for these samples.
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Fig. 1 Naturally acquired human anti-CSP antibodies are predominately IgG1, IgG3, and IgM, and can promote complement fixation to CSP. Antibodies
from malaria-exposed adults (n= 30 in each group) living in PNG (a, c-e) and Kenyan (b) were tested for IgG/IgM and complement-fixation to CSP by
ELISA. Results were standardized to arbitrary units (AU) based on malaria-naïve negative controls from Melbourne (seropositivity defined as AU > 1, shown
as dotted lines), and mean and range of duplicates were graphed (mean only for scatter plots). a,b IgG subclasses and IgM reactivity to CSP. The median,
interquartile range, and percentage of positive samples are shown. c Correlations between C1q-fixation and C4/C3/C3/C5b-C9-fixation to CSP (Spearman’s
correlation coefficient, rho). d Examples of C1q and C3-fixation to CSP by individual serum samples (V15, V32, V33, V45, and V46 from PNG donors, n= 5).
e C3-fixation to CSP by individual samples (V6, V7, V32, V37, and V43 from PNG donors, n= 5) in the presence of normal human serum (NHS) and serum
depleted of C1q (C1q dep.) (Wilcoxon matched-pairs signed rank test). Non-standardized data are shown, as only one Melbourne control (Melb.) was
tested. AU arbitrary units, CSP circumsporozoite protein, dep. depleted, ELISA enzyme-linked immunosorbent assay, Melb. Melbourne, NHS normal human
serum, PNG Papua New Guinea
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Of the IgG subclasses, IgG1 and IgG3 are the most
potent at activating the classical complement pathway.
As expected, anti-CSP IgG1 and IgG3 both strongly
correlated with C1q-fixation to CSP among a selection
of PNG adults (n = 30, rho = 0.829, 95% CI 0.662 to 0.
917 and rho = 0.792, 95% CI 0.592 to 0.900; p < 0.001 for
both tests). These antibodies also strongly correlated
with C4, C2, C3, and C5b-C9-fixation (Table 1), which
further supported that complement activation was via
the antibody-dependent classical pathway. To identify
which subclass was prevalent in samples with high levels
of C1q-fixing antibodies (above median AU = 2.2, n = 14)
, we compared the ratio of anti-CSP IgG1 to IgG3
(Additional file 1: Figure S3B). There tended to be an
increased IgG3 response, whereas the ratio of anti-CSP
IgG to IgM was highly variable, indicating that IgM may
be important in some individuals (Additional file 1: Fig-
ure S3C). Overall, characterizing the antibody response
is an important consideration when assessing functional
antibody responses.
P. falciparum sporozoites are susceptible to complement-
fixation by human antibodies
Initially, we tested antibodies from a highly reactive
PNG adult for the ability to promote complement-
fixation on sporozoites by ELISA (Fig. 4a; reactivity to
CSP shown in Additional file 1: Figure S4A). Consistent
with complement-fixation to CSP, we observed greater
C1q and C3-fixation in the presence of antibodies from
the PNG individual than the malaria-naïve individual. It
is noteworthy that some C3-fixation was observed in
the presence of malaria-naïve antibodies, suggesting
that C3 may bind directly to the sporozoite surface to
some extent, although this was substantially lower than
C3-fixation in the presence of malaria-exposed anti-
bodies. To confirm these findings, we tested antibodies
from a highly reactive Kenyan adult for complement-
fixation on sporozoites by Western blot (Fig. 4a; re-
activity to CSP shown in Additional file 1: Figure S4A).
C1q and enhanced C3-fixation occurred in the presence
of malaria-exposed antibodies, and some direct
C3-fixation was also observed in the presence of
malaria-naïve antibodies (repeat Western blots with
reduced exposure time to observe the C3b band more
clearly are shown in Additional file 1: Figure S4B).
These data show that naturally acquired antibodies
from malaria-exposed individuals promote complement
fixation on sporozoites via the antibody-dependent
classical pathway.
Sporozoite traversal inhibition by human and vaccine-
induced rabbit antibodies is enhanced by complement
We examined whether antibodies inhibited sporozoite
traversal, and whether this was enhanced in the presence
of an active complement. Sporozoites rely on their tra-
versal form of motility to pass through the sinusoidal
cell layer and several hepatic cells before encountering a
terminal hepatocyte for cellular invasion and develop-
ment [16]. We tested rabbit anti-CSP IgG previously
shown to fix the human complement to evaluate
whether the functional effect of antibodies to CSP was
enhanced by complement. Rabbit anti-CSP IgG inhibited
sporozoite traversal of HC-04 cells (compared to rabbit
pre-immune IgG), and inhibitory activity was substan-
tially enhanced in the presence of NHS compared to
HIS, whereby complement proteins were active and in-
active, respectively (Fig. 4b). To establish whether com-
plement also enhanced the function of human
antibodies that contain antibodies to CSP and other
Plasmodium antigens, we tested purified antibodies
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Fig. 2 Vaccine-induced rabbit anti-CSP IgG can fix human complement
proteins to CSP. Purified IgG from rabbit serum before (pre-imm.) and
after (a-CSP) CSP immunization was tested for IgG and complement-
fixation to CSP by ELISA. Results were corrected for background reactivity
using no-IgG controls, and the mean and range of the duplicates were
graphed. a IgG reactivity to CSP and (NANP)15 peptide (pre-immune IgG
shown with the open symbol was tested at 10 μg/ml). Results from two
independent experiments are shown. b C1q and C3-fixation to CSP
tested in the presence (+) and absence (−) of complement to confirm
specificity for complement fixation. a-CSP after CSP immunization, CSP
circumsporozoite protein, ELISA enzyme-linked immunosorbent assay,
IgG immunoglobulin G, pre-imm. before CSP immunization
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(including IgG and IgM) from a pool of malaria-
exposed Kenyan adults (n = 19 samples, Additional
file 1: Figure S5) and malaria-naïve Melbourne do-
nors, and quantified P. falciparum sporozoite trans-
versal (Fig. 4c). Kenyan antibodies inhibited NF54
sporozoite traversal (compared to Melbourne anti-
bodies) twofold higher in the presence of an active
complement compared to an inactive complement
(mean and range of two independent experiments:
46% [45.7 to 46.2%] and 18.2% [11.8 to 24.6%],
respectively). We confirmed this effect using sporozo-
ites from a second P. falciparum strain, NF166.C8,
whereby inhibition of antibody-mediated traversal was
observed only in the presence of active complement
and was not detected when antibodies were tested
with inactivated complement (30.7% [27.1 to 34.2%]
and −4.7% [−14.6 to 5.2%], respectively). Therefore,
the ability of antibodies to inhibit sporozoite traversal
was enhanced in the presence of active human
complement.
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Fig. 3 Naturally acquired human anti-CSP IgG correlates with the ability to promote C1q-fixation to CSP, despite individual differences in reactivity.
Antibodies from malaria-exposed adults living in PNG (a; N = 116) and Kenya (b; N = 104) were tested for IgG and C1q-fixation to CSP by ELISA. Results
were standardized to arbitrary units (AU) based on malaria-naïve negative controls from Melbourne (seropositivity defined as AU > 1, shown as dotted
lines), and the mean and range of duplicates were graphed (mean only for scatter plots). The left panels show correlations between IgG and C1q-
fixation to CSP (Spearman’s correlation coefficient, rho). The right panels show selected examples of IgG and C1q-fixation to CSP for individual serum
samples from PNG donors (V7, V49, V51, V52, and V53) and Kenyan donors (AR18, AR22, AR28, AR36, and AR47). AU arbitrary units, CSP circumsporozoite
protein, ELISA enzyme-linked immunosorbent assay, IgG immunoglobulin G, PNG Papua New Guinea
Table 1 Correlations between antibodies and complement fixation to CSP among malaria-exposed PNG adults (n = 30)
Antibody Rho C1q Rho C4 Rho C2 Rho C3 Rho C5b-C9
IgG 0.831 (0.666 to 0.919) 0.813 (0.625 to 0.912) 0.797 (0.606 to 0.901) 0.831 (0.666 to 0.919) 0.803 (0.616 to 0.904)
IgG1 0.829 (0.662 to 0.917) 0.839 (0.672 to 0.925) 0.830 (0.664 to 0.918) 0.895 (0.784 to 0.950) 0.745 (0.518 to 0.874)
IgG2 0.607 (0.276 to 0.809) 0.443 (0.046 to 0.720) 0.404 (0.008 to 0.691) 0.552 (0.198 to 0.779) 0.485 (0.108 to 0.740)
IgG3 0.792 (0.592 to 0.900) 0.795 (0.586 to 0.904) 0.788 (0.585 to 0.898) 0.801 (0.608 to 0.905) 0.754 (0.527 to 0.880)
IgG4 0.416 (0.039 to 0.689) – – – –
IgM 0.826 (0.656 to 0.916) 0.655 (0.363 to 0.830) 0.620 (0.325 to 0.805) 0.738 (0.506 to 0.870) 0.791 (0.596 to 0.898)
Spearman’s correlation coefficient (rho) and 95% CI between anti-CSP antibodies and complement fixation to CSP. Values greater than 0.7 are underlined. Only
significant correlations (p < 0.05) are shown
CI confidence interval, CSP circumsporozoite protein, PNG Papua New Guinea
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Antibody-mediated complement-fixation leads to
sporozoite death
We examined whether sporozoites were susceptible to
complement-mediated death since the formation of
the MAC can lead to membrane damage and possible
lysis of target cells. Cell death caused by complement
might be a contributing mechanism in the inhibition
of cell traversal. P. falciparum sporozoites were incu-
bated with rabbit anti-CSP IgG and NHS containing
an active complement, or C5-depleted serum as a
negative control as MAC-formation is C5 dependent
(Fig. 4d). We observed a twofold increase in the per-
centage of dead cells (PI positive) [35] when sporozo-
ites were incubated with complement and anti-CSP
IgG compared to pre-immune IgG (mean and range
of two independent experiments: 32.8% [28.1 to 37.
4%] and 16.1% [13.6 to 18.6%], respectively). Few PI-
positive cells were detected following treatment with
anti-CSP IgG and C5-depleted serum (4.4% [4.1 to 4.
7%]). These data show that anti-CSP IgG and comple-
ment proteins interact to enhance complement-
mediated sporozoite death.
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Fig. 4 Antibodies promote complement-fixation on P. falciparum sporozoites, which enhances antibody-mediated traversal inhibition and can lead to
sporozoite death. a Antibody samples from malaria-exposed (PNG and Kenyan) and malaria-naïve (Melbourne) individuals were tested for the ability to
fix human C1q and C3 to 3D7 P. falciparum sporozoites by ELISA and Western blot. ELISA samples (top panel) were tested in duplicate, and the mean
and range were graphed (C1q-fixation data is from two independent experiments). Western blot sporozoites (bottom panel) were incubated with human
antibody samples and normal human serum (NHS, active complement), and then washed and processed for Western blotting under reduced conditions.
Any complement proteins that had deposited on the sporozoite surface were detected using C1q- and C3-specific antibodies, and the sporozoite surface
antigen, CSP, was used as a loading control. b,c In vitro traversal inhibition of freshly dissected sporozoites incubated with HC-04 cells, in the presence of
NHS and heat-inactivated human serum (HIS). Each condition was tested in duplicate, and the mean and range were graphed. b Traversal inhibition of
NF54 sporozoites treated with rabbit anti-CSP IgG (compared to rabbit pre-immune IgG). c Traversal inhibition of NF54 and NF166.C8 sporozoites treated
with malaria-exposed Kenyan pool (compared to malaria-naïve Melbourne pool). Results from two independent experiments are shown. d Percentage of
dead 3D7 sporozoites (PI+ cells) treated with rabbit anti-CSP IgG and pre-immune IgG, in the presence of NHS or C5-depleted serum (C5dep.). The mean
and range of two independent experiments are graphed. a-CSP after CSP immunization, C5dep. C5-depleted serum, CSP circumsporozoite protein, ELISA
enzyme-linked immunosorbent assay, HIS heat-inactivated human serum, IgG immunoglobulin G, Melb. Melbourne, NHS normal human serum, OD
optical density, PI propidium iodide, PNG Papua New Guinea, pre-imm. before CSP immunization
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The NANP-repeat epitope is a target of C1q-fixing
antibodies
The NANP-repeat sequence is a major B-cell epitope of P.
falciparum CSP and a key target of antibodies generated
by the RTS,S vaccine [36]. Among PNG adults (n = 30),
55% were positive for C1q-fixation to (NANP)15 peptide
and 77% were positive for C1q-fixation to CSP. These var-
iables were strongly correlated (rho = 0.841, 95% CI 0.679
to 0.925; p < 0.001), suggesting that NANP was a signifi-
cant target of C1q-fixation to CSP (Fig. 5a). Among
Kenyan adults (n = 30), a lower proportion of individuals
were positive for C1q-fixation to (NANP)15 and CSP (36%
and 44%, respectively), and these variables only moder-
ately correlated (rho = 0.489, 95% CI 0.094 to 0.751; p = 0.
015) (Fig. 5b).
IgG and IgM isotype reactivity of PNG samples to
(NANP)15 positively correlated with C1q-fixation to CSP
(rho = 0.525, 95% CI 0.185 to 0.752; p = 0.004 and rho =
0.812, 95% CI 0.622 to 0.911; p < 0.001, respectively)
(Fig. 5a). To understand the role of antibody isotype
further, we categorized samples into four groups based
on low/high reactivity for NANP-specific IgG and IgM
(defined by median AU) and compared C1q-fixation
reactivity to CSP. Most samples were defined as either
low or high for both antibody isotypes. Those with high
NANP-IgG/IgM antibodies had significantly higher C1q-
fixation levels to CSP (by AU = 4.9) than individuals with
low NANP-IgG/IgM antibodies (p < 0.001) (Additional
file 1: Figure S6A). Interestingly, two samples with high
complement activity were classified as NANP-IgM high
0 4 8 12
0
5
10
15
20
NANP Antibodies and C1q-fixation to CSP (PNG Adults n=30)
NANP-IgG (AU)
C
S
P
-C
1q
(A
U
)
1
1
Rho=0.525; p=0.004
0 4 8 12
0
5
10
15
20
NANP-IgM (AU)
C
S
P
-C
1q
(A
U
)
1
1
Rho=0.812; p<0.001
0 6 12 18
0
5
30
CSP-C1q (AU)
N
A
N
P
-C
1q
(A
U
)
1
1
Rho=0.841; p<0.00135
20
0 2 4 6
0
5
10
15
NANP-IgM (AU)
C
S
P
-C
1q
(A
U
)
1
1
Rho=0.613; p=0.001
0 5 10
0
5
10
15
NANP Antibodies and C1q-fixation to CSP (Kenyan Adults n=30)
NANP-IgG (AU)
C
S
P
-C
1q
(A
U
)
1
1
Rho=0.425; p=0.034
0 5 10 15
0
4
8
20
24
CSP-C1q (AU)
N
A
N
P
-C
1q
(A
U
)
1
1
Rho=0.489; p=0.015
0
1
2
3
MAbs (ng/ml)
C
S
P
-C
1q
(O
D
45
0
nm
)
2H8-1
2H8-2a
3C1-1
3C1-3
8 16 32 62.52H8-1 2H8-2a 3C1-1 3C1-3
0.0
0.4
0.8
1.2
MAbs  (125 ng/ml)
Ig
G
(O
D
40
5
nm
) CSP
NANP
Mouse Anti-CSP  MAbs
a
b
c
Fig. 5 Antibodies that target the NANP epitope of CSP can promote C1q-fixation. Antibodies from malaria-exposed adults living in PNG (n = 30) (a)
and Kenya (n = 30) (b) were tested for IgG, IgM, and C1q-fixation to (NANP)15 peptide by ELISA, and correlated with C1q fixation to CSP (Spearman’s
correlation coefficient, rho). Results were standardized to arbitrary units (AU) based on malaria-naïve negative controls from Melbourne (seropositivity
defined as AU > 1, shown as dotted lines) and mean of duplicates were graphed. c Mouse anti-CSP MAbs 2H8-IgG1/IgG2a and 3C1-IgG1/IgG3 were
tested for CSP-IgG, NANP-IgG, and C1q-fixation to CSP by ELISA. Results were corrected for background reactivity using no-IgG controls, and the mean
and range of duplicates were graphed. AU arbitrary units, CSP circumsporozoite protein, ELISA enzyme-linked immunosorbent assay, IgG immunoglobulin
G, IgM immunoglobulin M, MAb monoclonal antibody, OD optical density, PNG Papua New Guinea
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and NANP-IgG low, suggesting the importance of IgM
for complement-fixation in these individuals. The IgG
and IgM isotype reactivity of Kenyan samples to
(NANP)15 moderately correlated with C1q-fixation to
CSP (rho = 0.425, 95% CI 0.024 to 0.709; p = 0.034 and
rho = 0.613, 95% CI 0.276 to 0.816; p = 0.001, respect-
ively) (Fig. 5b) Furthermore, individuals with high
NANP-IgG/IgM antibodies had only a minor increase in
C1q-fixation to CSP (by AU = 1.86) than individuals with
low NANP-IgG/IgM (p = 0.043) (Additional file 1: Figure
S6B). Collectively, these data show that NANP-specific
antibodies were variably associated with C1q-fixation to
CSP among individuals, and between the two malaria-
endemic populations.
To establish further that NANP-specific antibodies
mediate C1q-fixation to CSP, we tested mouse anti-
NANP MAbs (2H8 and 3C1) that had been subclass-
switched so that there were 2H8-IgG1/IgG2a and 3C1-
IgG1/IgG3 antibody pairs. All four MAbs demonstrated
similar IgG-reactivity against CSP and (NANP)15, but
only 2H8-IgG2a and 3C1-IgG3 effectively fixed C1q
compared to their IgG1 subclass counterparts, which is
known not to fix human complement (Fig. 5c) [31].
Age-associated acquisition of naturally acquired
complement-fixing antibodies to CSP
The bulk of malaria morbidity and mortality occurs in en-
demic areas where transmission is stable and relatively in-
tense, particularly in children aged less than 5 years. We,
therefore, investigated the acquisition of C1q-fixing anti-
bodies to CSP among young children (n = 59) compared to
adults (n = 16) living in a P. falciparum holoendemic area
in western Kenya when transmission was high. We also
compared complement-fixation responses to a major mero-
zoite surface protein, MSP2, which is an established target
of complement-fixing antibodies in blood-stage immunity
[37]. In this setting, young children are known to be acquir-
ing immunity to blood-stage infection and are susceptible
to severe malaria, whereas adults have more established im-
munity due to extensive exposure to infections. Study par-
ticipants were categorized into groups based on median
ages of 0.5, 1, 2, 5, and 35 years (ages were in the ranges 0.
3–0.7, 1–1.5, 1.8–3.0, 4.7–5.9, and 19.6–69.2 years, respect-
ively). Reactivity for C1q-fixation and IgG to CSP was rela-
tively low among children of all age groups and was
significantly higher among adults (p < 0.001 for both tests)
(Fig. 6a). In contrast, we observed higher reactivity for C1q-
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Fig. 6 Acquisition of C1q-fixing antibodies and total IgG to CSP and MSP2 antigens in malaria-exposed Kenyan children and adults. Kenyan children and
adults (N= 75) were categorized into groups based on the median ages 0.5, 1, 2, 5, and 35 years (n= 11, n= 14, n= 18, n= 16, and n= 16, respectively).
Samples were tested for C1q-fixation and total IgG to CSP (a) and MSP2 (b) by ELISA. Results were standardized to arbitrary units (AU) based on malaria-
naive negative controls from Melbourne (seropositivity defined as AU > 1, shown as dotted lines), and the mean of duplicates were graphed along with
the group median, interquartile range, and percentage of positive samples. Reactivity between two groups and more than two groups were compared
using the Mann–Whitney U test and Kruskal–Wallis test, respectively. AU arbitrary units, CSP circumsporozoite protein, ELISA enzyme-linked immunosorbent
assay, IgG immunoglobulin G, MSP2 Merozoite surface protein 2
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fixation to MSP2, a known target of naturally acquired im-
munity [29]. Interestingly, children in the age group with a
median of 5 years had C1q-fixing antibody levels similar to
adults (p = 0.275), which were higher than those observed
in younger children (p < 0.001). Taken together, these re-
sults suggest that complement-fixing antibodies to CSP are
poorly acquired during early childhood compared to the
merozoite antigen MSP2, and that C1q-fixing antibodies to
CSP are overall acquired more slowly than those to blood-
stage antigens.
High levels of C1q-fixing antibodies are associated with
protection against clinical malaria in children
From a longitudinal cohort study of children (N = 206,
5–14 years) who were resident in a malaria-endemic re-
gion of PNG [25], only a minority had antibodies that
promoted C1q-fixation to CSP (positivity 40%), weakly
correlating with anti-CSP IgG (rho = 0.280, 95% CI 0.140
to 0.409; p < 0.001). When stratified into four age groups
(≤8, 8.1–9, 9.1–10, and ≥10 years), there was no signifi-
cant association between age and C1q-fixing antibodies
(p = 0.211) (Fig. 7a). However, children with concurrent
parasitemia at the time of enrolment as determined by
the polymerase chain reaction showed significantly
higher C1q-fixation activity than uninfected children
(positivity 45% and 31%, respectively; p < 0.001) (Fig. 7a),
reflecting their recent exposure to sporozoites.
To obtain epidemiologic evidence supporting the
importance of antibody-mediated complement-fixation
to CSP in acquired immunity to malaria, we investigated
whether the minority of PNG children with high levels
of functional antibodies had a reduced risk of clinical
malaria. Children were treated for malaria and then
actively monitored for the duration of the study,
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Fig. 7 High levels of C1q-fixing antibodies to CSP are associated with protection against clinical malaria in children. PNG children (N= 206) were tested for
C1q-fixation to CSP by ELISA. Results were standardized to arbitrary units (AU) based on malaria-naïve negative controls from Melbourne (seropositivity
defined as AU> 1, shown as dotted lines). a C1q-fixation to CSP was categorized by age (≤8, 8.1–9, 9.1–10, and≥10 for n= 47, n= 39, n= 38, and n= 71,
respectively), and parasitemic status at enrolment by PCR. Each sample was tested in duplicate, and the mean value was used to generate box plots. The
top, center, and bottom horizontal lines represent the 75th percentile, median, and 25th percentile, respectively. The upper and lower whiskers represent
the highest and lowest values within the 1.5×-interquartile range, respectively. Values that exceed this range are presented as symbols. Reactivity between
two groups and more than two groups was compared using the Mann–Whitney U test and Kruskal–Wallis test, respectively. b Kaplan–Meier survival curve
showing the cumulative proportion of children who had experienced an episode of malaria during the follow-up (time in days), stratified into three groups
based on C1q-fixation reactivity: negative (AU< 1), low positive (bottom 50% of positive samples, 1 < AU≤ 1.525), and high positive (top 50% of positive
samples, AU > 1.525), as shown in blue, red, and green, respectively (n= 116, n= 39, and n= 39, respectively; p= 0.0438, Wilcoxon Breslow test, unadjusted
for confounders). AU arbitrary units, CSP circumsporozoite protein, ELISA enzyme-linked immunosorbent assay, PCR polymerase chain reaction, PNG Papua
New Guinea
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enabling us to establish any association between C1q-
fixing antibody levels at enrolment and the subsequent
risk of developing clinical malaria. Children were divided
into three response groups based on C1q-fixation
reactivity: (i) negative (AU < 1), (ii) low positive (bottom
50% positive samples, 1 < AU ≤ 1.525), and (iii) high
positive (top 50% of positive samples, AU > 1.525)
(Additional file 1: Figure S7). In a Kaplan–Meier survival
analysis, children with high levels of C1q-fixation had a
lower rate of malaria during the follow-up (Fig. 7b).
Importantly, we found that children with high levels of
C1q-fixing antibodies at enrolment had a significantly
reduced risk of clinical malaria compared to children
who were negative for C1q-fixing antibodies (Cox propor-
tional hazards model; HR = 0.39 [0.18–0.87], p = 0.020),
which remained significant after adjusting for potential
confounders of age, location of residence, and parasitemia
at baseline (adjusted HR = 0.42 [0.19–0.94], p = 0.034). A
significant association was not observed for children with
low C1q-antibodies compared to those who were negative
(HR = 0.70 [0.38–1.38], p was not significant and adjusted
HR = 0.69 [0.35–1.37], p = 0.2). Furthermore, there was no
significant association between IgG to CSP and risk of
malaria (adjusted HR 0.50 [0.19–1.32] comparing children
with high IgG responses compared to IgG-negative indi-
viduals). Although the prevalence of naturally acquired
functional anti-CSP antibodies was generally low, these
data suggest that high levels of C1q-fixing antibodies are
associated with naturally acquired anti-malarial immunity
and protection against disease.
Discussion
Developing highly efficacious vaccines requires know-
ledge of the functional mechanisms that contribute to
protection against malaria, and the identification of cor-
relates of protective immunity. Here we show that natur-
ally acquired human anti-CSP antibodies can function
by fixing C1q and activating the classical comple-
ment pathway, and this activity significantly correlated
with IgG1, IgG3, and IgM antibodies. C1q-fixing anti-
bodies were also shown to target the central NANP-
repeat region of CSP. Importantly, we provide the first
direct evidence that P. falciparum sporozoites are sus-
ceptible to human complement via the antibody-
dependent classical pathway, resulting in enhanced tra-
versal inhibition and sporozoite death in vitro. Further-
more, we found that the natural acquisition of C1q-
fixing antibodies to CSP in children occurs more slowly
than observed for blood-stage antigens. Although poorly
acquired in general, the minority of children who ac-
quired high levels of C1q-fixing antibodies to CSP had a
significantly reduced risk of developing clinical malaria,
which identified the first functional correlate of immun-
ity to sporozoites in human studies. Together, these
findings reveal that antibodies to CSP and P. falciparum
sporozoites can function by activating human comple-
ment, and provide initial epidemiological evidence link-
ing antibody function and protective immunity.
To detect functional anti-CSP antibodies, we mea-
sured their ability to fix C1q, which is unique to the
antibody-dependent classical complement pathway, as
well as downstream complement proteins. There were
strong correlations between C1q fixation and C4/C2/C3/
C5b-C9 fixation demonstrating that C1q-fixation alone
was a sufficient measure of complement activity, which
we used in subsequent cohort experiments.
We demonstrated that immune antibodies promote
the deposition and activation of human complement
against whole P. falciparum sporozoites and had func-
tional effects. While anti-CSP antibodies can directly in-
hibit sporozoite traversal and invasion in vitro [17–19],
high antibody concentrations have generally been
required and the relationship between function and pro-
tection has not been established. Furthermore, the pres-
ence of anti-CSP IgG alone is an insufficient correlate of
protection in humans. We found that naturally acquired
human antibodies had only weak activity in the direct
inhibition of P. falciparum sporozoite traversal, but ac-
tivity was substantially enhanced by an active human
complement. When using sporozoites from the NF54
line, there was a more than twofold increase in inhibi-
tory activity when antibodies were tested in the presence
of an active complement (compared to an inactivated
complement), whereas substantial traversal inhibition of
NF166.C8 sporozoites was seen only when antibodies
were tested with active complement present. Inhibiting
sporozoite traversal may be important, as it is essential
for establishing liver-stage infection in animals [16, 38].
Mouse studies of the rodent species, P. berghei, reported
that glycan-specific antibodies activated the mouse
complement and inhibited the traversal and invasion of
sporozoites [39]. Interestingly, this was not mediated by
murine IgG2a, which we have shown is capable of fixing
human C1q. There are important differences between
human malaria immunity and murine models. Murine
models typically use the rodent malaria P. berghei,
which has substantial biological and functional differ-
ences from P. falciparum, including in the major target
antigen CSP, as P. berghei does not have the major
NANP epitope of P. falciparum CSP. Furthermore,
complement activity in laboratory mice is much lower
than for human complement, which plays an important
role in immunity [40]. Murine immune responses to
Plasmodium infection are typically dominated by mur-
ine IgG1, which does not fix complement, whereas hu-
man IgG1 and IgG3 dominate human responses and
both subclasses potently activate complement. The fu-
ture development of new animal models of malaria that
Kurtovic et al. BMC Medicine  (2018) 16:61 Page 13 of 17
better represent antibody–complement interactions
may be valuable for vaccine development. Future re-
search to define further the antibody titers, types, and
specificity required for optimal complement fixation
and functional effects would be valuable to help inform
vaccine development.
Antibodies alone cannot kill target cells, but our find-
ings suggest that they can mediate this effect by recruit-
ment and activation of complement. We directly showed
that incubation with antibodies and complement can
lead to sporozoite death. It has previously been proposed
that murine antibody–complement interactions lead to
morphological changes and bleb formation in P. falcip-
arum sporozoites [41]. However, in that prior study,
complement-fixation and activation were not directly
shown and the potential effect of the complement was
not quantified (only qualitative data were presented),
and antibodies were predominantly murine IgG1, which
cannot interact with complement, as we have also shown
[31]. Interestingly we found that sporozoites were par-
tially susceptible to direct complement attack, as indi-
cated by some direct C3 deposition and cell death.
However, complement susceptibility was enhanced two-
fold in the presence of immune antibodies.
The NANP-repeat sequence is a known B-cell epitope
of CSP, and an important target of RTS,S-induced anti-
bodies [36]. We found this epitope also to be a target
C1q-fixation using synthetic NANP peptide and
NANP-specific MAbs. This supports future investigation
of whether RTS,S-induced antibodies mediate
complement-fixation, as they are known to predomin-
ately target this epitope. NANP-specific antibodies can
neutralize sporozoite function in vitro [42], and can re-
duce liver-stage burden in humanized mice that are sus-
ceptible to P. falciparum [8] or mice challenged with
transgenic P. falciparum/P. berghei sporozoites [43], al-
though high antibody concentrations appear to be re-
quired for function. Our data suggest that complement
may substantially enhance the function of these anti-
bodies, reducing the critical concentrations needed to
mediate functional effects. There were significant corre-
lations between C1q-fixation to NANP and CSP, and be-
tween NANP-specific IgG/IgM and C1q-fixation to CSP,
but the strength of correlations varied between the PNG
and Kenyan populations. It is possible that antibodies to
other regions of CSP mediate complement-fixation, such
as epitopes in the C-terminal and N-terminal regions,
which warrants further investigation.
We identified a subset of individuals from PNG and
Kenya with high anti-CSP IgG reactivity that demon-
strated a weak ability to fix C1q. This highlights that
total IgG reactivity is not wholly reflective of functional
activity, and may explain why measuring anti-CSP IgG
alone is a poor correlate of protective immunity. Anti-
CSP IgG can directly fix C1q, and IgM is also likely to
play some role, as we observed high levels of anti-CSP
IgM in selected individuals that strongly fixed C1q.
Anti-CSP IgG was predominately the IgG1 and IgG3
subclasses, which are known to active complement.
However, IgG2 and IgG4 were also detected in some in-
dividuals, which may negatively impact C1q-fixation by
outcompeting the complement-fixing subclasses; there-
fore, the overall isotype and subclass profile is important
for functional activity. Other antibody factors, such as
epitope specificity, affinity, and glycosylation, are also
important in determining function.
A striking new finding is that children with high levels
of C1q-fixing antibodies to CSP had a significantly re-
duced risk of clinical malaria compared to children who
had no detectable functional antibodies. Previously, no
association between anti-CSP antibodies and protection
in malaria-exposed populations has been found [44, 45].
In contrast, we show important initial epidemiologic evi-
dence of the potential role of anti-CSP antibodies that
fix complement in malaria immunity, supported by find-
ings on the functional outcomes of antibody–comple-
ment interactions. This is the first identification of a
functional antibody response to sporozoite antigens that
is associated with protective immunity in malaria-
exposed children, suggesting that this is a significant
new correlate of immunity. Our findings suggest that al-
though the natural development of strong complement-
fixing antibodies occurs only in a minority of children,
when such antibodies do develop, they contribute to
protective immunity. These findings support future in-
vestigation of whether C1q-fixing antibodies are induced
by vaccines such as RTS,S, and whether functional anti-
bodies are associated with vaccine efficacy and could be
used a correlate of protection.
The cell-free high-throughput assay to detect and
quantify functional, complement-fixing antibodies to
CSP, which we developed in this study, could be applied
in large-scale clinical trials for vaccine evaluation.
Although this may not wholly represent all interactions
that occur on the sporozoite surface, CSP is a well-
validated antigen that is known to be the major target of
naturally acquired immunity to sporozoites [11, 46, 47]
and is the basis of the leading vaccine candidate, RTS,S
[12]. Future studies should investigate other potentially
important sporozoite antigens as targets of complement-
fixing antibodies and the importance of non-repeat CSP
epitopes, which may have important implications in vac-
cine development, and whether complement activation
leads to additional effects or outcomes.
Conclusions
In summary, this study demonstrates for the first time
that immune antibodies fix and activate human
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complement against CSP and P. falciparum sporozoites,
which inhibited sporozoite traversal and lead to sporozo-
ite death. These data provide key knowledge on antibody
functional mechanisms against sporozoites, and help us
to identify which antibody types and epitopes are im-
portant in mediating anti-malarial immunity. We also
obtained promising evidence that a strong level of C1q-
fixing antibodies to CSP is associated with protection
against clinical malaria, and may be a valuable correlate
of protective immunity. This is the first evidence of a
functional antibody response to sporozoites associated
with protection against malaria in children. The future
application of these approaches to quantify functional
immunity in vaccine trials may greatly aid our under-
standing of how vaccines work and why efficacy has
been suboptimal in trials to date. The antibody C1q-
fixation assay may be a suitable correlate of protective
immunity in vaccine development and trial evaluation,
and studies of acquired human immunity. Defining the
functional mechanisms that confer protective immunity
against malaria is essential for developing and evaluating
much-needed highly efficacious malaria vaccines. These
findings have strong translational significance by reveal-
ing a mechanism of anti-sporozoite immunity, and
thereby enabling the development of strategies to
maximize this effector mechanism in the development
of highly efficacious malaria vaccines.
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